Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Randomized Controlled Trial
. 2019 Mar 28;380(13):1226-1234.
doi: 10.1056/NEJMoa1811714.

Overall Survival With Fulvestrant Plus Anastrozole in Metastatic Breast Cancer

Affiliations
Free PMC article
Randomized Controlled Trial

Overall Survival With Fulvestrant Plus Anastrozole in Metastatic Breast Cancer

Rita S Mehta et al. N Engl J Med. .
Free PMC article

Erratum in

Abstract

Background: We previously reported prolonged progression-free survival and marginally prolonged overall survival among postmenopausal patients with hormone receptor-positive metastatic breast cancer who had been randomly assigned to receive the aromatase inhibitor anastrozole plus the selective estrogen-receptor down-regulator fulvestrant, as compared with anastrozole alone, as first-line therapy. We now report final survival outcomes.

Methods: We randomly assigned patients to receive either anastrozole or fulvestrant plus anastrozole. Randomization was stratified according to adjuvant tamoxifen use. Analysis of survival was performed by means of two-sided stratified log-rank tests and Cox regression. Efficacy and safety were compared between the two groups, both overall and in subgroups.

Results: Of 707 patients who had undergone randomization, 694 had data available for analysis. The combination-therapy group had 247 deaths among 349 women (71%) and a median overall survival of 49.8 months, as compared with 261 deaths among 345 women (76%) and a median overall survival of 42.0 months in the anastrozole-alone group, a significant difference (hazard ratio for death, 0.82; 95% confidence interval [CI], 0.69 to 0.98; P = 0.03 by the log-rank test). In a subgroup analysis of the two strata, overall survival among women who had not received tamoxifen previously was longer with the combination therapy than with anastrozole alone (median, 52.2 months and 40.3 months, respectively; hazard ratio, 0.73; 95% CI, 0.58 to 0.92); among women who had received tamoxifen previously, overall survival was similar in the two groups (median, 48.2 months and 43.5 months, respectively; hazard ratio, 0.97; 95% CI, 0.74 to 1.27) (P = 0.09 for interaction). The incidence of long-term toxic effects of grade 3 to 5 was similar in the two groups. Approximately 45% of the patients in the anastrozole-alone group crossed over to receive fulvestrant.

Conclusions: The addition of fulvestrant to anastrozole was associated with increased long-term survival as compared with anastrozole alone, despite substantial crossover to fulvestrant after progression during therapy with anastrozole alone. The results suggest that the benefit was particularly notable in patients without previous exposure to adjuvant endocrine therapy. (Funded by the National Cancer Institute and AstraZeneca; ClinicalTrials.gov number, NCT00075764.).

Figures

Figure 1.
Figure 1.
Enrollment, Randomization, and Follow-up of the Patients.
Figure 2.
Figure 2.. Kaplan–Meier Curves for Progression-free Survival, According to Trial Group.
Curves are shown for the overall trial population (Panel A) as well as for the subgroup of patients who had not received adjuvant endocrine therapy previously (Panel B).
Figure 3.
Figure 3.. Kaplan–Meier Curves for Overall Survival, According to Trial Group.
Curves are shown for the overall trial population (Panel A) as well as for the subgroup of patients who had not received adjuvant endocrine therapy previously (Panel B).
Figure 4.
Figure 4.. Subgroup Analysis of Overall Survival.
Shown are the results of subgroup analyses of the treatment effect on overall survival. Hazard ratios for death in the group that received combination therapy with fulvestrant plus anastrozole, as compared with the group that received anastrozole alone, are shown along with 95% confidence intervals.

Comment in

  • Fulvestrant enables better outcomes.
    Sidaway P. Sidaway P. Nat Rev Clin Oncol. 2019 Jun;16(6):337. doi: 10.1038/s41571-019-0211-7. Nat Rev Clin Oncol. 2019. PMID: 30967645 No abstract available.

Similar articles

See all similar articles

Cited by 12 articles

See all "Cited by" articles

Publication types

MeSH terms

Associated data

Feedback